{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:19:13Z","timestamp":1790921953931,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.hoc.2024.05.014","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T22:55:47Z","timestamp":1719874547000},"page":"831-849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ductal Carcinoma In Situ"],"prefix":"10.1016","volume":"38","author":[{"given":"Brittany L.","family":"Bychkovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.G.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hoc.2024.05.014_bib1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/0008-5472.CAN-16-2346","article-title":"Precancer atlas to drive precision prevention trials","volume":"77","author":"Spira","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.014_bib2","article-title":"Advances and challenges in cancer immunoprevention and immune interception","volume":"12","author":"Stanton","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.014_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajpath.2018.07.031","article-title":"Morphologic and molecular features of breast ductal carcinoma in\u00a0situ","volume":"189","author":"Sanati","year":"2019","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.014_bib4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in\u00a0situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2024.05.014_bib5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/95.2.160","article-title":"Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women","volume":"95","author":"Veronesi","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.014_bib9","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2024.05.014_bib10","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.22.02900","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: A 10-Year Follow-Up of TAM-01 study","volume":"41","author":"Lazzeroni","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/bcr938","article-title":"The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer","volume":"6","author":"Allred","year":"2004","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clbc.2013.08.002","article-title":"Palpable ductal carcinoma in\u00a0situ: analysis of radiological and histological features of a large series with 5-year follow-up","volume":"13","author":"Sundara Rajan","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archsurg.1989.01410010035007","article-title":"Nonpalpable in\u00a0situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment","volume":"124","author":"Schwartz","year":"1989","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5","article-title":"Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice","volume":"66","author":"Silverstein","year":"1990","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.014_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y","article-title":"Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma","volume":"86","author":"Fisher","year":"1999","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.014_bib16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","article-title":"Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in\u00a0situ of the breast","volume":"31","author":"Toss","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2021.12.023","article-title":"Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma","volume":"185","author":"Risom","year":"2022","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.014_bib18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cncr.34679","article-title":"Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status","volume":"129","author":"Lowry","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"33","key":"10.1016\/j.hoc.2024.05.014_bib20","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","article-title":"Surgical excision without radiation for ductal carcinoma in\u00a0situ of the breast: 12-year results from the ECOG-ACRIN E5194 study","volume":"33","author":"Solin","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10021","key":"10.1016\/j.hoc.2024.05.014_bib21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in\u00a0situ (IBIS-II DCIS): a double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"issue":"10021","key":"10.1016\/j.hoc.2024.05.014_bib22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","article-title":"Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in\u00a0situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Margolese","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2024.05.014_bib23","article-title":"Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial","author":"Cuzick","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.35009","article-title":"Adherence to hormonal therapy after surgery among older women with ductal carcinoma in\u00a0situ: Implications for breast cancer-related adverse health events","volume":"130","author":"Mitchell","year":"2024","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.hoc.2024.05.014_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer","volume":"91","author":"Gail","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2024.05.014_bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2024.05.014_bib27","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1158\/1078-0432.CCR-20-4213","article-title":"Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease","volume":"27","author":"DeCensi","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.hoc.2024.05.014_bib28","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.014_bib29","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-021-06141-7","article-title":"The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies","volume":"188","author":"Smith","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.014_bib31","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/GME.0b013e318252e46d","article-title":"Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys","volume":"19","author":"Ethun","year":"2012","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.014_bib32","doi-asserted-by":"crossref","first-page":"e0271725","DOI":"10.1371\/journal.pone.0271725","article-title":"Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells","volume":"17","author":"Messier","year":"2022","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.014_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1940-6207.CAPR-19-0315","article-title":"Effect of bazedoxifene and conjugated estrogen (duavee) on breast cancer risk biomarkers in high-risk women: a pilot study","volume":"12","author":"Fabian","year":"2019","journal-title":"Cancer Prev Res (Phila)"},{"issue":"24","key":"10.1016\/j.hoc.2024.05.014_bib34","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.2174\/092986709788803042","article-title":"The effects of tamoxifen on immunity","volume":"16","author":"Behjati","year":"2009","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-020-01788-4","article-title":"The immunomodulatory effects of endocrine therapy in breast cancer","volume":"40","author":"Huang","year":"2021","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib36","doi-asserted-by":"crossref","first-page":"pky063","DOI":"10.1093\/jncics\/pky063","article-title":"Epidemiology, biology, treatment, and prevention of ductal carcinoma in\u00a0situ (DCIS)","volume":"2","author":"Punglia","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1998.16.2.441","article-title":"Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17","volume":"16","author":"Fisher","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2024.05.014_bib38","series-title":"Breast cancer conservation therapy","author":"Jordan","year":"2024"},{"issue":"35","key":"10.1016\/j.hoc.2024.05.014_bib39","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1200\/JCO.2007.11.4686","article-title":"Significance of multifocality in ductal carcinoma in\u00a0situ: outcomes of women treated with breast-conserving therapy","volume":"25","author":"Rakovitch","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2024.05.014_bib40","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0960-9776(19)31120-8","article-title":"Estimating the magnitude of clinical benefit of local therapy in patients with DCIS","volume":"48","author":"Hwang","year":"2019","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3322\/caac.21321","article-title":"Cancer statistics: breast cancer in\u00a0situ","volume":"65","author":"Ward","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"33","key":"10.1016\/j.hoc.2024.05.014_bib42","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2016.68.3573","article-title":"Society of surgical oncology-american society for radiation oncology-american society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in\u00a0situ","volume":"34","author":"Morrow","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.014_bib43","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","article-title":"Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in\u00a0situ","volume":"28","author":"Rudloff","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.014_bib44","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A\u00a0biological signature for breast ductal carcinoma in\u00a0situ to predict radiotherapy benefit and assess recurrence risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.014_bib45","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1245\/s10434-016-5322-0","article-title":"Utilization of axillary surgery for patients with ductal carcinoma in\u00a0situ: a report from the national cancer data base","volume":"23","author":"Miller","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.amjsurg.2016.04.019","article-title":"Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in\u00a0situ? a systematic literature review and meta-analysis","volume":"213","author":"El Hage Chehade","year":"2017","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib48","doi-asserted-by":"crossref","first-page":"pkz052","DOI":"10.1093\/jncics\/pkz052","article-title":"Long-term outcomes of sentinel lymph node biopsy for ductal carcinoma in\u00a0situ","volume":"3","author":"Hung","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.014_bib49","first-page":"223","article-title":"Long-term follow-up of in\u00a0situ carcinoma of the breast","volume":"11","author":"Eusebi","year":"1994","journal-title":"Semin Diagn Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.014_bib50","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.21069","article-title":"The natural history of low-grade ductal carcinoma in\u00a0situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up","volume":"103","author":"Sanders","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.014_bib51","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/modpathol.2014.141","article-title":"Continued observation of the natural history of low-grade ductal carcinoma in\u00a0situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up","volume":"28","author":"Sanders","year":"2015","journal-title":"Mod Pathol"},{"issue":"16","key":"10.1016\/j.hoc.2024.05.014_bib52","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.014_bib53","doi-asserted-by":"crossref","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in\u00a0situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.014_bib54","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in\u00a0situ - The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.014_bib55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyx059","article-title":"Current approach and future perspective for ductal carcinoma in\u00a0situ of the breast","volume":"47","author":"Kanbayashi","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"41","key":"10.1016\/j.hoc.2024.05.014_bib56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in\u00a0situ of the breast","volume":"2010","author":"Correa","year":"2010","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.014_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","article-title":"RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in\u00a0situ comparing radiotherapy with observation","volume":"33","author":"McCormick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.hoc.2024.05.014_bib58","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in\u00a0situ: long-term report from NRG oncology\/RTOG 9804","volume":"39","author":"McCormick","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","article-title":"A\u00a0population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone","volume":"152","author":"Rakovitch","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw256","article-title":"Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in\u00a0situ","volume":"109","author":"Rakovitch","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.014_bib61","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A\u00a0multigene expression assay to predict local recurrence risk for ductal carcinoma in\u00a0situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-021-06187-7","article-title":"DUCHESS: an evaluation of the ductal carcinoma in\u00a0situ score for decisions on radiotherapy in patients with low\/intermediate-risk DCIS","volume":"188","author":"Rakovitch","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.014_bib63","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","article-title":"The clinical utility of DCISionRT((R)) on radiation therapy decision making in patients with ductal carcinoma in\u00a0situ following breast-conserving surgery","volume":"28","author":"Shah","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2024.05.014_bib64","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1200\/JCO.2016.67.8532","article-title":"Cost effectiveness of the oncotype DX DCIS score for guiding treatment of patients with ductal carcinoma in\u00a0situ","volume":"34","author":"Raldow","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.014_bib65","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.prro.2019.10.005","article-title":"Assessing the financial toxicity of radiation oncology patients using the validated comprehensive score for financial toxicity as a patient-reported outcome","volume":"10","author":"D'Rummo","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.014_bib66","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41416-020-01223-7","article-title":"Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects","volume":"124","author":"Liu","year":"2021","journal-title":"Br J Cancer"},{"issue":"14 Suppl","key":"10.1016\/j.hoc.2024.05.014_bib67","first-page":"S292","article-title":"Novel blood-based early cancer detection: diagnostics in development","volume":"26","author":"Beer","year":"2020","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib68","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"issue":"7761","key":"10.1016\/j.hoc.2024.05.014_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"issue":"6499","key":"10.1016\/j.hoc.2024.05.014_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb9601","article-title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention","volume":"369","author":"Lennon","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib71","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2022.06.012","article-title":"Re: clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation Set","volume":"82","author":"Rossi","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib72","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2022.01.012","article-title":"New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening","volume":"40","author":"Hackshaw","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/cas.14697","article-title":"Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer","volume":"112","author":"Chin","year":"2021","journal-title":"Cancer Sci"},{"issue":"10409","key":"10.1016\/j.hoc.2024.05.014_bib74","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.014_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194818","article-title":"Cell-Free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial","volume":"14","author":"Neal","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.014_bib76","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","article-title":"Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study","volume":"24","author":"Nicholson","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.014_bib77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cas.12880","article-title":"Novel combination of serum microRNA for detecting breast cancer in the early stage","volume":"107","author":"Shimomura","year":"2016","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib78","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41416-021-01550-3","article-title":"The current status of risk-stratified breast screening","volume":"126","author":"Clift","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0163278720984203","article-title":"A\u00a0Latent Disease Model to Reduce Detection Bias in Cancer Risk Prediction Studies","volume":"44","author":"Aleshin-Guendel","year":"2021","journal-title":"Eval Health Prof"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib80","doi-asserted-by":"crossref","first-page":"e1009020","DOI":"10.1371\/journal.pcbi.1009020","article-title":"Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts","volume":"17","author":"Trentham-Dietz","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib81","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/0962280217754232","article-title":"Estimating the frequency of indolent breast cancer in screening trials","volume":"28","author":"Shen","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib82","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41591-022-01746-x","article-title":"The future of early cancer detection","volume":"28","author":"Fitzgerald","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib83","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-016-0675-7","article-title":"Genetic predisposition to ductal carcinoma in\u00a0situ of the breast","volume":"18","author":"Petridis","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.014_bib84","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.acra.2019.09.025","article-title":"Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma","volume":"27","author":"Lamb","year":"2020","journal-title":"Acad Radiol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib85","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jmri.25712","article-title":"Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in\u00a0situ: Correlating histologic grade and receptor status","volume":"46","author":"Chou","year":"2017","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib86","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1148\/radiol.12111368","article-title":"In\u00a0vivo assessment of ductal carcinoma in\u00a0situ grade: a model incorporating dynamic contrast-enhanced and diffusion-weighted breast MR imaging parameters","volume":"263","author":"Rahbar","year":"2012","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib87","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1148\/radiol.211839","article-title":"Ductal Carcinoma in Situ: State-of-the-Art Review","volume":"302","author":"Grimm","year":"2022","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40644-023-00526-1","article-title":"Contrast enhanced mammography: focus on frequently encountered benign and malignant diagnoses","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Imag"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.014_bib89","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1148\/radiol.211412","article-title":"Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance","volume":"302","author":"Cozzi","year":"2022","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.014_bib90","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/tbj.13408","article-title":"Role of preoperative breast dual-energy contrast-enhanced digital mammography in ductal carcinoma in\u00a0situ","volume":"25","author":"Vignoli","year":"2019","journal-title":"Breast J"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.014_bib91","doi-asserted-by":"crossref","first-page":"e0162740","DOI":"10.1371\/journal.pone.0162740","article-title":"Dual-Energy Contrast-Enhanced Spectral Mammography: Enhancement Analysis on BI-RADS 4 Non-Mass Microcalcifications in Screened Women","volume":"11","author":"Cheung","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.014_bib92","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","article-title":"The natural history of ductal carcinoma in\u00a0situ of the breast: a review","volume":"97","author":"Erbas","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib93","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-011-1430-5","article-title":"Characterizing the impact of 25 years of DCIS treatment","volume":"129","author":"Ozanne","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.014_bib94","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/bjc.2012.151","article-title":"The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS","volume":"106","author":"Wallis","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2024.05.014_bib96","doi-asserted-by":"crossref","first-page":"786286","DOI":"10.3389\/fimmu.2021.786286","article-title":"Intercepting premalignant, preinvasive breast lesions through vaccination","volume":"12","author":"Zachariah","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.014_bib97","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2217\/imt-2016-0052","article-title":"Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2\/neu-positive breast cancer: progress and potential","volume":"8","author":"De La Cruz","year":"2016","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.014_bib98","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/0008-5472.CAN-06-4038","article-title":"Targeting HER-2\/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion","volume":"67","author":"Czerniecki","year":"2007","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2024.05.014_bib99","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in\u00a0situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.014_bib100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-015-0584-1","article-title":"Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer","volume":"17","author":"Datta","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.014_bib101","doi-asserted-by":"crossref","first-page":"e1207032","DOI":"10.1080\/2162402X.2016.1207032","article-title":"Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)\/HER2(pos) early breast cancer","volume":"6","author":"Lowenfeld","year":"2017","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.014_bib102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1940-6207.CAPR-22-0388","article-title":"Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ","volume":"16","author":"O'Shea","year":"2023","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:25:09Z","timestamp":1720067109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0889858824000637"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.014","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ductal Carcinoma In Situ","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}